2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies
Dickson S, Mallinckrodt C, Rogula B, Powell L, Potashman M, Coric V, L’Italien G, Hendrix S. Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies. Neurology And Therapy 2024, 1-13. PMID: 39287752, DOI: 10.1007/s40120-024-00661-2.Peer-Reviewed Original ResearchComposite scaleDisease-modifying therapiesItem-level dataDisease progressionDetect clinically meaningful effectsPlacebo arm dataValidity scalesMeasure disease progressionTreatment effectsClinical declineDMT effectClinically meaningful effectChange scoresAssess treatment effectsDetect disease progressionTreatment outcomesSlow disease progressionMeaningful effectSensitive to disease progressionNeurodegenerative disease progressionItemsResponse outcomesPatient populationStandard itemsNatural history data
2022
POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute Management
Harris L, L'Italien G, Croop R, Coric V, Robbins J, Woolley J, OConnell T. POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute Management. Value In Health 2022, 25: s140. DOI: 10.1016/j.jval.2021.11.675.Peer-Reviewed Original ResearchAcute managementPatient population